Prosecution Insights
Prosecution Insights
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| No statute on record | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GURLEY, JAMI MICHELLE | 1 | 45.0% | +25.5% |
| BERHANE, SELAM | 1 | 61.3% | +55.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17618140 | NOVEL INTERLEUKIN-2 VARIANTS FOR THE TREATMENT OF CANCER | BERHANE, SELAM | 127d overdue |
| 17784305 | CYTOKINE-BASED BIOACTIVATABLE DRUGS AND METHODS OF USES THEREOF | GURLEY, JAMI MICHELLE | 34d |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17784305 | CYTOKINE-BASED BIOACTIVATABLE DRUGS AND METHODS OF USES THEREOF | GURLEY, JAMI MICHELLE | 1647 | Other | Final Rejection | 34d | Pending | Jun 10, 2022 |
| 17618140 | NOVEL INTERLEUKIN-2 VARIANTS FOR THE TREATMENT OF CANCER | BERHANE, SELAM | 1675 | §112 | Non-Final OA | 127d overdue | Pending | Dec 10, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial